1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1670
  5. Art Unit 1675
  6. Examiner Essex

Examiner Essex Laura A

1675-ESSEX-LAURA-A

Employment Information

Art Unit:1675 — Drug, bio-affecting and body treating compositions
Group:1670 — Virology, Viral Immunology, And Viral Pathogens, Neurology, Receptors, Cytokines & Recombinant Hormones and Immunoassays and related devices
Classes: 424 — Drug, bio-affecting and body treating compositions
514 — Drug, bio-affecting and body treating compositions
435 — Chemistry: molecular biology and microbiology
530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
436 — Chemistry: analytical and immunological testing
506 — Combinatorial chemistry technology: method, library, apparatus
Phone:(571) 272-1103
Email:laura.essex@uspto.gov
Location:VA 22314
Title:Pat Examnr Gen Chem
Service:4 years
Grade:GS-12

Grant Rate and Difficulty Ranking

84
3-Year Grant rate: 44% over 36 cases
Difficulty: Very Hard
Difficulty Percentile: 84th

With Examiner Essex, you have a 44% chance of getting an issued patent by 3 years after the first office action. Examiner Essex is a very hard examiner and in the 84th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Essex, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1675

Examiner Essex's grant rate is lower than that of Art Unit 1675 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Essex 1.4
Art Unit 1675 1.6

Interview Benefit

Grant Rate without Interview

Examiner Essex has granted 13 of 29 cases without any applicant-requested interviews for a grant rate of 45%.

Grant Rate with Interview

Examiner Essex has granted 3 of 7 cases with at least one applicant-requested interview for a grant rate of 43%.

Interview Benefit

With Examiner Essex, conducting an interview decreases your chance of getting a patent granted by 4%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
17014399 Anti-Il-23p19 Antibody Formulations Rejection information available with a Premium Stats subscription. See our pricing. Patented View
17906569 Hybrid Interferons For Treating Viral Infections Abandoned View
17594289 Cell-Penetrating Conjugate Systems Abandoned View
17914209 Anti-Psma Antibody-Exatecan Analogue Conjugate And Medical Use Thereof Abandoned View
17434796 Antibody Drug Conjugate Loaded With Binary Toxins And Its Application Patented View
17775067 Lag-3 Antagonist Therapy For Melanoma Abandoned View
17680041 Anti-Her2 Antibody-Drug Conjugates And Uses Thereof Patented View
17432331 Methods For Labeling Eukaryotic Cells From A Multicellular Organism As Well As For Treating And/or Diagnosing A Cancer Using Modified Monosaccharide Compounds Patented View
17079553 Nmda Antagonist Prodrugs Patented View
18455685 Amidated Peptides And Their Deamidated Counterparts Displayed By Hla-A*02 For Use In Immunotherapy Against Different Types Of Cancers Abandoned View
16946345 Methods For Treating Synucleopathic Conditions Abandoned View
16746497 Anti-Cmet Antibody Drug Conjugates And Methods For Their Use Abandoned View
17882087 Method Of Treating Chronic Myeloid Leukemia Using Pegylated Interferon And Tyrosine Kinase Inhibitor Abandoned View
17272151 Compositions And Methods For Enhancing Triplex And Nuclease-Based Gene Editing Abandoned View
17112587 Compositions And Methods Comprising An Anti-Cd47 Antibody In Combination With A Tumor Targeting Antibody Abandoned View
17262940 Il-21 Prodrugs And Methods Of Use Thereof Patented View
17445419 Compositions Of Phosphorylated Tau Peptides And Uses Thereof Abandoned View
17408038 Alzheimer's Disease Assay In A Living Patient Abandoned View
18892253 Antibody-Conjugates For Targeting Of Tumours Expressing Ptk7 Patented View
17614487 Conformation-Specific Epitopes In Tau, Antibodies Thereto And Methods Related Thereof Abandoned View
17530775 Methods Of Using A Bispecific Antigen-Binding Construct Targeting Her2 For The Treatment Of Biliary Tract Cancers Patented View
17600919 Water Soluble Adjuvant And Composition Containing Same Patented View
16969481 Combination Therapies Comprising Schweinfurthin Compounds For Treating Cancer Patented View
17228481 Methods Of Treating Neurodegenerative Disease With Substituted N-Hexanoic-L-Tyrosine-L-Isoleucine-(6)-Aminohexanoic Amide Analogues Patented View
18448006 Amidated Peptides And Their Deamidated Counterparts Displayed By Hla-A*02 For Use In Immunotherapy Against Different Types Of Cancers Abandoned View
18172769 Anti-Cmet Antibody Drug Conjugates And Methods For Their Use Abandoned View
18451884 Amidated Peptides And Their Deamidated Counterparts Displayed By Hla-A*02 For Use In Immunotherapy Against Different Types Of Cancers Abandoned View
17742686 Agonists Of Trem2 Patented View
18455683 Amidated Peptides And Their Deamidated Counterparts Displayed By Hla-A*02 For Use In Immunotherapy Against Different Types Of Cancers Abandoned View
17438203 Immunoconjugates Targeting Her2 Abandoned View
17255589 Pyridopyrimidinone Derivatives For Use As Axl Inhibitors Patented View
18190643 Methods Of Permeabilizing The Blood Brain Barrier Abandoned View
18451883 Amidated Peptides And Their Deamidated Counterparts Displayed By Hla-A*02 For Use In Immunotherapy Against Different Types Of Cancers Abandoned View
18630179 Conjugates Comprising Cleavable Beta-Glucuronide-Containing Linkers Patented View
18448260 Amidated Peptides And Their Deamidated Counterparts Displayed By Hla-A*02 For Use In Immunotherapy Against Different Types Of Cancers Abandoned View
18167245 Treatment Methods For Als Patients Patented View
17728183 Chimeric Receptors Targeting Adgre2 And/or Clec12a And Uses Thereof Patented View
18448017 Amidated Peptides And Their Deamidated Counterparts Displayed By Hla-A*02 For Use In Immunotherapy Against Different Types Of Cancers Abandoned View
17248432 Treatment Of Demyelinating Disorders Patented View
16822083 Antigen Binding Fragments Conjugated To A Plurality Of Fc Isotypes And Subclasses Abandoned View
17052142 Surrogate Marker And Method For Tumor Mutation Burden Measurement Abandoned View
18823422 Anti-Pd-1 Antibody-Attenuated Il-2 Immunoconjugates And Uses Thereof Patented View
16968452 Methods And Compositions For Therapeutic Protein Delivery Patented View
18300834 Anti-Cd38 Antibodies And Formulations Abandoned View
17267483 Method For Suppression Of Hepapitis B Virus Replication And Hepapitis B Virus Surface Antigen Secretion Abandoned View
16087060 Use Of Nucleosome-Transcription Factor Complexes For Cancer Detection Abandoned View
17275838 Novel Lilrb4 Antibodies And Uses Thereof Patented View
16974114 Antibody Compositions Comprising Fc Mutations And Site-Specific Conjugation Properties For Use In Treating Cancer, Immunological Disorders, And Methods Thereof Patented View
17056270 Compounds For The Treatment Or Alleviation Of Disorders Associated With Tau Aggregates Patented View
17744139 Method Of Reducing Tet2 Mutant Allele Burden Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.